The test is used in the early identification of prostate cancer. Credit: Korawat photo shoot / Shutterstock.

Biomerica has gained approval from the UAE Ministry of Health and Prevention (MOHAP) for its Fortel prostate-specific antigen (PSA) screening test used in the early identification of prostate cancer.

Utilising a finger-prick blood sample, the test claims to generate ‘accurate’ outcomes within ten minutes by measuring elevated PSA levels, an early marker of the disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This rapid diagnostic tool aims to alleviate the strain on healthcare systems and enhance patient outcomes by enabling early identification.

Following the introduction of the EZ Detect colon disease at-home screening test in Dubai, which received government insurance reimbursement, Biomerica is currently focused on similar achievements with the Fortel test, having established partnerships with distributors and secured essential regulatory approvals in the region.

The company noted that the test has shown potential in clinical evaluations. A study demonstrated a sensitivity, specificity, and accuracy of 100%, 95%, and 97.5% respectively.

Further research conducted at Ain Shams University’s Faculty of Medicine in Egypt validated the effectiveness of the test, which achieved a sensitivity of 97.2%, a specificity of 96.2%, and an accuracy of 96.7%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company continues to focus on delivering accessible, accurate, affordable, accurate diagnostic tools for early disease detection and treatment.

In May 2023, the company announced the validation of its inFoods IBS test for use with finger stick (capillary) patient whole blood samples for irritable bowel syndrome.

Biomerica’s portfolio continues to grow as the company develops and markets diagnostic and therapeutic products for point-of-care and clinical laboratory applications.